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ABSTRACT:
Mesenchymal stem or stromal cells (MSCs) are precursor cells that play important 
roles in tumorigenesis. MSCs are recruited to tumors from local and distant sources 
to form part of the tumor microenvironment. MSCs influence tumor progression 
by interacting with cancer cells, endothelial cells, immune cells, and cancer stem 
cells, in a context-dependent network. This review aims to synthesize this emerging 
yet controversial field to identify key questions regarding the mechanisms of MSC 
mobilization and survival in blood; homing to tumors, metastases, and premetastatic 
sites; spatiotemporal organization and differentiation; and interaction with immune 
cells and cancer stem cells. Understanding the fundamental biology underlying 
mesenchymal stem cell and tumor interactions has the potential to inform our 
knowledge of cancer initiation and progression as well as lead to novel therapeutics 
for cancer. Furthermore, knowledge of endogenous mechanisms can be used to 
“program” exogenous MSCs for targeted chemotherapeutic delivery to tumors and 
metastases. Emerging studies will provide crucial insight into the mechanisms of 
tumor interactions with the whole organism including MSCs.
1. INTRODUCTION
Early molecular genetic studies on tumors 
primarily focused on cell-autonomous mechanisms 
of tumor progression. For instance, both growth and 
invasion were understood in terms of intracellular 
signaling pathways, regulation of cell cycle progression, 
apoptosis, and cytoskeletal dynamics (1). However, 
it has become increasingly evident that tumor cells 
non-cell autonomously interact with both their local 
microenvironment and the entire organism (2). 
At the most basic level, tumor cells interact with 
their surroundings: the microenvironment or stroma 
composed of tumor promoting and opposing cells, soluble 
molecules, and extracellular matrix components (2). 
Tumor-associated cells include heterogeneous fibroblasts, 
neutrophils, macrophages, lymphocytes, endothelial cells, 
and nerve cells, among others. The extracellular matrix, 
in collaboration with soluble factors, provides signals for 
the modulation of cell cycle progression, apoptosis and 
migration of both tumors and associated stromal cells 
(3). Unlike the classical conception of a “disordered” 
tumor, these components form an intricate network of 
signaling and crosstalk, with subdivisions of processes 
and components (2).
Recent evidence indicates that non-hematopoietic 
stromal cells can originate from mesenchymal stem 
or stromal cells (MSCs), and MSCs themselves form a 
critical part of the tumor stroma. MSC are adult, non-
hematopoietic multipotent stem cells that can be isolated 
from fat and bone marrow, among other tissues. MSCs 
are traditionally characterized by their plastic adherence, 
tri-lineage differentiation to adipocytes, chrondrocytes, 
and osteoblasts, expression of characteristic surface 
marker proteins (e.g., CD44, CD90, and CD106) (4). 
Local tissue-resident MSCs are important players in 
tissue homeostasis that are activated to proliferate and 
differentiate during tissue remodeling and inflammation. 
Under normal conditions, they may be associated with the 
local vasculature or other cells types (5). In many cases, Oncotarget 2013; 4: 651-664 652 www.impactjournals.com/oncotarget
however, MSCs are recruited from more distant organs to 
tumor and injury sites, including both the bone marrow   
(BM) and adipose tissue (6,7). 
In recent years, there has been considerable interest 
in the use of MSCs as trophic vehicles for delivery of 
drugs, proteins, and other therapeutic agents specifically 
to tumors due to their lack of immune rejection and natural 
and specific ability to home to and integrate into tumors. 
The excellent phenotypic stability of MSCs in cell culture 
has facilitated their application in these technologies. In 
addition, MSCs may be easily modified, both genetically 
and non-genetically, for drug delivery, enhanced and more 
specific homing, and single-cell niche visualization—all 
with minimal impact on the MSC phenotype (8).
Here, we evaluate the role of both endogenous and 
exogenous MSCs and in some cases, MSC-like cells, 
as critical players in tumor progression. By endogenous 
MSCs we refer to those MSCs that are recruited to 
cancers from within the body; in contrast, exogenous 
MSCs are those that are cultured ex vivo before delivery 
to an experimental subject or patient. We emphasize 
that the process of MSC mobilization into the systemic 
circulation, survival in the blood, recruitment to tumors, 
differentiation, and distribution within tumors critically 
regulates tumor progression. The pleiotropic effects 
of MSCs include roles in regulating cancer stem cells, 
tumor proliferation, migration, immune cell recruitment 
and  function,  and  angiogenesis.  Moreover,  we  find 
extensive evidence that MSCs can be used as potent and 
safe tumor tropic vehicles for genetically engineered and 
conventional drug delivery to tumors. Together, these 
examples emphasize that the basic biology of tumor-
associated cells can be engineered for both translation to 
the clinic and as experimental tools for investigation of 
regulatory interactions within the tumor. We hope that this 
article will both serve as a useful synthesis of the field 
as well as a source of intriguing open questions to be 
addressed in the future.
2. MSCS CONTRIBUTE TO THE TUMOR 
STROMA
As tumors recruit many untransformed cells during 
cancer progression, many researchers naturally explored 
the contribution of endogenous stem cells to cancers. A 
growing body of evidence suggests that MSCs derived 
from both local (e.g., adipose tissue) and distant (e.g., 
bone marrow) sources contribute to the tumor stroma 
(Figure 1; Supplementary Table 1 and references therein). 
In tumors arising in the bone marrow or in metastases to 
the bone marrow, tumor cells may exploit endogenous 
hematopoietic stem cell niches for survival or proliferation 
(9,10). MSCs themselves have been proposed to form a 
critical part of the hematopoietic stem cell (HSC) niche 
(11), and tumor cells may compete for the HSC niche 
(9). Also, endogenous MSC-like cells  (based on in vitro 
morphology  and  cell  surface  marker  profiling)  have 
been isolated from the bone marrow of chronic myeloid 
leukemia patients (12).
In addition to the bone marrow, MSCs are present 
in other tissues and may be recruited by tumor cells 
to form part of the microenvironment. Using ex vivo 
cultured MSCs as a model for endogenous local MSCs, 
several groups have shown important contributions of 
MSCs to the tumor stroma. For instance, in a rodent 
experimental glioma model, exogenous MSCs injected 
Figure 1: MSCs are recruited to tumors from local and distant (systemic) sources. Red arrows show regulatory interactions 
of tumor cells on MSC biology; dark blue arrows show cell movements and action of MSCs on tumor cells. (a) Although the precise 
mechanisms remain to be determined, local (tissue-resident) MSCs can be recruited to tumors via tumor-derived cytokines, chemokines, 
and growth factors. (b) In addition, MSCs can be derived from distant (systemic) sources, including the bone marrow, adipose tissue, and 
possibly other organs. The signals mediating MSC mobilization to blood, survival in blood, and the attraction of MSCs to tumors are not 
known.Oncotarget 2013; 4: 651-664 653 www.impactjournals.com/oncotarget
into the tumor were found to closely follow cancer 
invasive extensions and microsatellites (13), and human 
MSCs transplanted locally into the tumor were able to 
migrate to and survive in the cancer mass (14). These 
results suggest that molecular interactive cues might 
exist between glioma cells and MSCs (13). In addition, 
locally injected exogenous MSCs preferentially localized 
to experimental intraperitoneal tumors (15). Significantly, 
real time non-invasive data with exogenous luciferase-
expressing Human MSCs (hMSCs) indicated that hMSCs 
incorporate into tumors where they may contribute to the 
tumor microenvironment (15,16).
Endogenous MSC-like cells populate the uninjured 
skin and other organs, and contribute to wounded eye 
and skin epithelium, injury-induced arterial intimal 
hyperplasia, and ischemic myocardium (17–21). This 
raises the question of to what extent endogenous 
MSCs can integrate into tumors, which several studies 
have directly addressed. In several elegant studies, 
immunodeficient  mice  were  sublethally  irradiated 
and transplanted with green fluorescent protein (GFP) 
labeled bone marrow to label bone-marrow derived cells, 
including MSCs. It was found that bone marrow-derived 
myofibroblasts were present in pancreatic cancers and that 
the proportion of bone marrow-derived cells increased as 
the tumor progressed (22,23). Moreover, in a similar study 
using GFP-labeled bone marrow, about half of ovarian 
tumor stromal cells were derived from the bone marrow; 
in this case accounting for 20% of the myofibroblasts and 
pericytes and 70% of the fibroblasts. A sizeable proportion 
of stromal cells originated from MSCs and more than 75% 
of MSC-derived tumor stromal cells were fibroblast-like, 
while up to 10% were myofibroblasts (6). This observation 
extends to inflammatory models of gastric cancer, where 
20%  of  all  cancer  myofibroblasts  were  bone  marrow 
derived  (24).  Interestingly,  myofibroblast-like  cells 
increased in number in the BM of tumor-containing versus 
tumor-free mice, with in vitro evidence suggesting that 
MSCs can give rise to myofibroblasts (24). Intriguingly, 
there is preliminary evidence of bone marrow contribution 
to the stroma of human tumors. Worthley et al. performed 
an analysis of tumor tissue specimens obtained from 
female allogenic bone marrow transplant patients that 
had received bone marrow from male donors and found 
myofibroblasts in gastrointestinal tumors that possessed 
Y-chromosomes (25). 
In addition to the bone marrow, local resident MSC-
like cells may also contribute to the tumor stroma. Using 
transplantation of GFP-positive bone marrow, Kidd et al 
found that approximately half of the tumor stromal cells 
were of non-bone marrow origin (6). In contrast, almost 
all endothelial cells and the majority of pericytes were 
derived from cells outside the bone marrow. Furthermore, 
transplantation of fluorescently labeled adipose tissue as 
a source of stromal cells adjacent to the tumor revealed 
a significant contribution of adipose-derived cells to the 
tumor stroma, particularly pericytes. Although the exact 
nature of the cells giving rise to tumor stromal elements 
is not clear, these results indicate that local and distant 
stromal sources may contribute to the tumor stroma 
and that their relative contributions to different stromal 
elements may differ (6). In support of this hypothesis, 
a recent study found that endogenous local MSC-like 
adipose stromal cells mobilize and engraft to the tumor 
in an obese mouse model of cancer, emphasizing the 
importance of systemic communication between organs 
and cancer progression (7). 
Intriguingly, tumor cells themselves could be a 
source of cells with MSC-like characteristics. Battula 
et al  (2010) demonstrated that immortalized human 
mammary epithelial cells induced to undergo epithelial-
mesenchymal transition  (EMT) in vitro by Twist, Snail, 
or transforming growth factor β (TGFβ) overexpression 
recapitulated many of the features of MSCs. Namely, 
they expressed MSC surface markers and gained the 
ability to differentiate to chrondrocytes, osteoblasts and 
adipocytes (26). This raises the interesting possibility that 
tumor cells may give rise to their own stroma through 
transdifferentiation. Interestingly, recent work showed 
differentiation of glioblastoma stem cells to pericytes 
(which may resemble MSCs), dependent on TGF-β (27).
Finally, numerous studies have demonstrated 
that ex vivo cultured “exogenous” MSCs (but not their 
differentiated progeny) efficiently home to tumors and 
metastases after intravenous injection (Supplementary 
Table 1 and references therein). In an uninjured mouse, 
exogenous intravenously-injected MSCs rapidly 
accumulate within lungs and are cleared to other organs 
such as the liver within days. Moreover, MSCs are not 
detectable in the mouse body after 7 days (16). This 
pattern of accumulation followed by clearance within 
days is markedly similar to that of non-reactive acrylic 
microspheres, suggesting that passive accumulation 
dominates the biodistribution of MSCs under normal 
physiological conditions (27). A significant body of work 
has firmly established that exogenously cultured MSCs are 
capable of selectively homing to and surviving in a variety 
of pre-established solid tumors (breast, colon, melanoma, 
and others) while being excluded from normal tissues. The 
evidence for this has been obtained using MSC-specific 
PCR,  immunohistochemistry  (IHC)  (29–31)  and  non-
invasive, real-time bioluminescence imaging (16,32,33), 
nuclear magnetic resonance imaging (MRI) (34), positron 
emission  tomography    (PET)  (35),  and  radionuclide 
imaging (35). In addition to systemic targeting of large 
solid tumors, MSCs (but not differentiated fibroblasts) 
have been shown to home to and be retained in metastases 
and other small tumors, while not accumulating in normal 
tissues. This was demonstrated using methods including 
immunohistochemistry (29,36–38), and bioluminescence 
imaging (16,32) in cancers ranging from breast to prostate 
to melanomas. These studies have provided a model for Oncotarget 2013; 4: 651-664 654 www.impactjournals.com/oncotarget
studying MSC homing to tumors and emphasized the 
possibility of using MSCs as drug delivery vehicles to 
tumors.
3. MECHANISMS OF MSC RECRUITMENT 
AND HOMING TO TUMORS
Mobilization from the bone marrow and other 
organs represents the first key step in MSC homing to 
tumors. There is evidence that endogenous MSCs can 
mobilize from the BM and other tissues to the  peripheral 
blood under both normoxia and hypoxia, inflammation, 
and injury conditions (18–20). Moreover, this process 
is tightly regulated, with endogenous MSC-like cells 
only being isolated and cultured from the blood of mice 
subjected to femoral artery injury, but not from the blood 
of uninjured mice (19). Similarly, CD29-positive MSC-
like cells could be isolated and cultured from blood of 
mice with burn-injured corneas, but not from uninjured 
mice (18). Although multiple studies have found that 
the bone marrow plays key roles in contributing to the 
tumor stroma (Supplementary Table 1 and references 
therein), major unresolved questions remain regarding the 
mobilization of MSCs from the bone marrow and homing 
to tumors (6,20,24).
Inflammatory  cytokines  have  been  suggested  to 
mediate the mobilization of MSCs from their tissues of 
origin, as their concentration increases during injury and 
other disease processes, concomitant with an increase in 
circulating MSCs (18–20). In response to cornea burn 
injuries, it was found that the 11-amino acid neuropeptide, 
substance P, was elevated in the blood of injured animals 
and was sufficient to mobilize endogenous MSCs to the 
blood (18). In addition, other systemic signals may also 
be critical in mobilizing MSCs to blood. For example, BM 
MSC have been shown to respond to sympathetic nervous 
system (SNS) signals to regulate hematopoietic stem cells 
(11). Since SNS signals have been observed to influence 
tumor progression (39), the possibility of regulating MSC 
mobilization through the SNS in the context of tumors 
is an intriguing area of research that has not yet been 
explored. Despite some key observations, the initial key 
steps in MSC mobilization and intravasation into the blood 
stream remain largely unexplained.
Following mobilization from distant sources 
into the systemic vascular system, MSCs must then 
extravasate and engraft at tumors. Much work dedicated 
to understanding immune cell homing has established that 
the steps of interaction between cells in the circulation and 
endothelial cells  (ECs) include capture, rolling, activation, 
arrest, adhesion strengthening, crawling, transendothelial 
migration and establishment within target tissues. 
Selectins, selectin ligands, integrins-immunoglobulin 
superfamily receptors  (e.g., vascular cell adhesion 
Figure 2: The physical parameters and cell surface molecules of MSCs cooperate to induce active homing of MSCs 
to tumors. Endothelial cells are green; MSCs are blue; and tumor cells are pink. Although the mechanisms of MSC homing are poorly 
understood, they likely involve partially overlapping steps of deceleration in the blood flow (which may be partially physical – here 
depicted as bulging endothelial cells), rolling, adhesion, transmigration through the endothelium, and migration into surrounding tissues. 
The possible molecular determinants are indicated. The elucidation of the MSC homing mechanism to tumors will facilitate the development 
of drugs for inhibition of this process (endogenous MSCs), or for understanding how ex vivo cultured MSCs can be engineered to be used 
as effective and specific drug delivery vehicles.Oncotarget 2013; 4: 651-664 655 www.impactjournals.com/oncotarget
molecule-1 – VCAM-1), chemokines and their receptors, 
and other molecules are involved in this process (40). 
Despite controversy over the exact mechanism (Figure 2), 
there is strong evidence that MSCs have the capacity to 
home to sites of inflammation. Moreover, MSC adhesion 
to the endothelium is greatly enhanced by activation of 
the endothelium with pro-inflammatory cytokines such 
as tumor necrosis factor α (TNFα) (41). As many cancers 
induce significant inflammatory responses, this suggests 
a possible mechanism regulating the tropism of MSCs 
for solid tumors (42). Recent data with inhibitors to 
chemokine (C-X-C motif) ligand 12/stromal cell-derived 
factor 1 (CXCL12/SDF-1) receptor CXCR4 and TGFβ 
receptor suggest that endogenous MSC homing to tumors, 
differentiation to myofibroblasts, and/or survival require 
CXCR4 (24). In addition several studies have suggested 
that tumor-derived platelet-derived growth factor (PDGF), 
epidermal  growth  factor  (EGF),  vascular  endothelial 
growth factor (VEGF), and interleukin-6 (IL-6) may be 
required for localization, integration and/or survival in 
tumors (43–45).
The role of cytokines and chemokines  in the 
context of MSCs has also been examined and found to 
induce survival and engraftment and promote enhanced 
slow crawling (46), adhesion (41,46), spreading on the 
endothelium (46), transmigration (46,47), and chemotaxis 
(48,49). A recent study compared the transmigration 
of MSCs, leukocytes, and cancer cells. In contrast to 
leukocytes, but similar to cancer cells, MSC transmigration 
does not involve lamellopodia or invadosomes, but instead 
involves “blebbing” of their membranes. Although the 
regulation and molecular mechanisms remain to be 
characterized, blebbing and VCAM-1 have been proposed 
to be important for establishing transmigration interactions 
with the endothelium (47). 
The BBB is a well-regulated barrier to cell 
trafficking  to  the  brain  that  normally  prevents 
extravasation of immune and other cells to the brain 
parenchyma (50). Interestingly, exogenous MSCs appear 
to be capable of crossing the blood-brain barrier (BBB) 
and contribute to experimental gliomas when administered 
via the carotid artery(13). At 1 hour following injection, 
MSCs were clustered near blood vessels, suggesting entry 
of the MSCs through the endothelial cells. By 3-4 days 
post injection, human MSCs were dispersed throughout 
the tumor, but were not present within normal adjacent 
and distant brain tissue. Similar results were obtained in a 
similar glioma model (31), and robust MSC transmigration 
of in vitro models of the BBB have been observed (51). 
As MSCs have been additionally utilized as therapeutics 
for a variety of central nervous system disorders, (47, 51) 
understanding the mechanisms by which they bypass the 
BBB has clear clinical implications for both cancer and 
other disorders.
It is likely that MSC homing to tumors involves 
interplay between active recruitment via chemokines and 
inflammatory processes and passive entrapment in the 
vasculature. Exogenously delivered MSCs are physically 
and molecularly non-specifically entrapped in sites with 
small  blood  vessels,  including  “filtering  organs”  like 
the lungs, liver, and spleen (52,53). Intriguingly, use of 
a vasodilator concomitant with injection of exogenous 
Figure 3: MSC differentiation within tumors. MSCs have been found to differentiate to (a) osteoblasts (red), adipocytes (yellow), 
or other cell types; (b) pericytes; (c) cancer stem cell niche cells; and (d) tumor associated fibroblasts. The precise function of each of these 
cell types remains to be determined. Each step may be targeted for inhibition by therapies, based on their function in promoting or inhibiting 
tumor progression or initiation.Oncotarget 2013; 4: 651-664 656 www.impactjournals.com/oncotarget
MSCs led to a markedly altered biodistribution of MSCs, 
with a significant decrease in entrapment in the lungs (52). 
Moreover, treatment of exogenous MSCs with an integrin 
α4 blocking antibody results in entrapment of significantly 
fewer cells in the lung following intravenous injection 
(54). Thus, we reason that the physical parameters 
of MSCs collaborate with molecular determinants to 
ultimately dictate homing and engraftment. Unraveling the 
relative contributions of molecular signals and physical 
parameters in MSC homing to tumors will reveal both new 
biology and novel targets for therapeutic intervention.
4. MSC ORGANIZATION AND 
DIFFERENTIATION WITHIN TUMORS 
Although MSC tropism for tumors is now relatively 
well established, their ultimate fate - incorporation into 
tumors, differentiation, communication with cancer cells, 
other stromal cells, and cancer stem cells - in the tumor 
remains unclear. We have summarized the key findings in 
literature regarding MSC organization and differentiation 
within tumors in Figure 3 and Supplementary Table 2. 
Briefly,  MSCs  incorporate  into  tumors  as  single  cells 
and clumps that may be associated with both necrotic 
regions and the vasculature. MSCs have been found to 
contribute to multiple cellular components of the stroma, 
including fibroblasts, periendothelial cells, adipocytes, 
and osteoblasts, among others. In particular, MSC-derived 
cells localized to lung metastases underwent osteogenic 
differentiation, while MSCs localized to subcutaneous 
tumors adopted an adipogenic fate. These results indicate 
that the lung and subcutaneous locations of tumors 
may  have  different  microenvironmental  influences  on 
tumor and MSC fate (32). Interestingly, changing the 
microenvironment with irradiation of subcutaneous 
tumors was sufficient to alter intravenously injected mouse 
MSC distribution within it. Whereas MSCs were mostly 
associated with blood vessels in non-irradiated tumors, 
irradiation caused MSCs to become more localized to 
the tumor parenchyma, which could have important 
implications for therapy that utilizes MSCs as delivery 
vehicles (33). Furthermore, recent studies have suggested 
that MSCs may form a part of the cancer stem cell (CSC) 
niche (Figure 3c). Specifically, it was found that human 
MSCs transplanted into the bone marrow can expand 
the  putative breast cancer CSC population via a cytokine 
loop involving IL6 and CXCL7 (45). Moreover, MSCs 
were able to home to the tumor, distribute throughout the 
stroma mostly as single cells, and closely associate with 
the putative CSCs. 
Tumor MSC organization or differentiation is 
a regulated event that depends on the tumor context 
(e.g.,  see  Klopp  et  al.,  2007  and  Wang  et  al.,  2009) 
(32,33). Mechanistically, MSC organization, survival, 
and differentiation depends in part on CXCR4, TGF-β, 
Wnt5a,  IL-6  signaling,  supplied  by  myofibroblasts, 
which serve as niche cells for MSCs in tumors. TGF-β 
induced the differentiation of MSCs to myofibroblasts, in 
a CXCR4-dependent manner. Myofibroblasts expressed 
bone morphogenic protein 4 (BMP4), Wnt5a, and IL-6, 
and MSCs expressed the BMP inhibitor Gremlin-1 when 
in close proximity to myofibroblasts. Also, expression 
Figure 4: MSC tumor progression promoting functions. (a) MSCs may promote tumor cell proliferation and inhibit cell death. (b) 
MSCs may promote angiogenesis within tumors. (c) MSCs may inhibit some immune functions, while promoting others. (d) MSCs may 
promote tumor metastasis, possibly at multiple steps  (from initial dissemination to formation of novel niches in distal tissues). (e) MSCs 
may regulate cancer stem cell self-renewal and differentiation.Oncotarget 2013; 4: 651-664 657 www.impactjournals.com/oncotarget
of the Wnt inhibitors DKK1 and Shh was dependent on 
co-culture of MSCs with myofibroblasts, suggesting a 
delicate signaling network between the two cell types 
(24). Understanding the functional relevance of MSCs in 
relationship to both their organization and differentiation 
will be essential for fully defining the roles of MSCs in 
cancer.
5. THE FUNCTION OF MSCS IN TUMORS
MSCs regulate the tumor phenotype by affecting the 
initiation and growth of tumors, angiogenesis, metastasis, 
immune system function and cancer stem cell function, 
in a context-dependent manner which we summarized in 
details in Figure 4 and Supplementary Table 3. In addition, 
endogenous bone marrow and adipose tissue-derived 
MSCs may directly contribute to the tumor stroma. As 
alluded to above, MSCs derived from the bone marrow 
may give rise to tumor myofibroblasts and promote the 
growth of gastric tumors (24). In addition, both adipose 
and bone marrow MSC sources may contribute to the 
tumor stroma, with the bone marrow contributing to 
the  tumor-associated  fibroblasts  and  adipose  tissue 
contributing to the vascular and fibrovascular stroma (6).
MSCs are known to secrete a number of anti-
apoptotic and pro-proliferative cytokines and growth 
factors that may act directly on tumor cells (Da Silva 
Meirelles et al., 2008; Wu et al., 2010). For example, MSCs 
promote tumor chemotherapy resistance via secretion of 
omega-3 and oxo family fatty acids (55). Moreover, MSCs 
differentiate to tumor pericytes and MSC-secreted VEGF 
and other pro-angiogenenic molecules induce tumor 
angiogenesis (7,43). Also, tumor-distal or resident MSCs 
enhance cancer cell motility, extravasation to secondary 
sites (56), and possibly also intravasation to and survival 
in blood. Tumor associated fibroblast  (TAF) secreted 
CXCL-12  (SDF-1) was found to directly promote the 
growth of CXCR4 expressing tumors in vivo and in vitro 
(57). A large proportion of MSCs contribute to the TAF 
population, raising the possibility of MSC involvement in 
activation of this pathway (6). The exciting possibility that 
MSCs may contribute to the pre-metastatic niche remains 
to be explored (58). In addition, MSC-like cells contribute 
to the hematopoietic niche and thus may contribute to 
bone marrow metastases (59).
MSCs also interact with immune cells in tumors, 
inhibiting or promoting inflammation depending on the 
context. While MSCs may inhibit leukocyte proliferation 
in solid tumors (60), MSCs may promote proliferation of 
leukemia cells (12). MSCs decrease the proliferation and 
differentiation of B cells via prostaglandin E2 (PGE2). 
Moreover, MSCs suppress activation of helper T cells 
via PGE2, indoleamine 2,3-dioxygenase  (IDO), TGFβ, 
hepatocyte growth factor (HGF), nitric oxide (NO), and 
Figure 5: Combinatorial cancer therapy and detection using engineered exogenous MSCs.  (a) Cell surface chemistry using 
biotin-streptavidin conjugation or enzymatic modification can be used to attach multiple ligands  (yellow and green) on the MSC surface. 
Different combinations of these ligands can be used to combinatorally target MSCs to specific tissues in the body  (e.g., tumor). (b) Genetic 
engineering techniques may be used to express anti-tumorigenic molecules including interferons (IFN) and prodrug converting enzymes.   
(c) Drugs  (small orange circles) can be encapsulated in micro or nanoparticles  (large red circles), which in turn can be engulfed by MSCs. 
(d) Drug release from MSCs will cause tumor cell death. (e) Spatiotemporal micronenvironment sensing  (SMS): Tumor microenvironment 
, intercellular signaling, and tumor progression may be imaged via molecular probes such as surface-conjugated FRET aptamers.Oncotarget 2013; 4: 651-664 658 www.impactjournals.com/oncotarget
haem oxygenase 1, while the activation of cytotoxic T 
cells may be inhibited but regulatory T cells promoted by 
human leukocyte antigen G5 (HLA-G5) (61). Also, MSC-
derived IDO, PGE2, and TGFβ decrease the activation and 
killing activity of natural killer cells, while IL-6, IL-10, 
TGFβ, PGE2, HGF, and macrophage colony-stimulating 
factor (M-CSF) inhibit the differentiation and function of 
dendritic cells. IL-6 also negatively regulates neutrophils 
(62,63).
Also, MSCs form part of the cancer stem cell 
niche and modulate their function, at least in part via 
BMP, PGE2, and β-catenin signaling (45,64). Two recent 
reports suggested that human bone marrow (45)- or tumor-
derived (65) MSC-like cells  (with differentiation capacity, 
immunophenotype, and colony formation ability similar 
to MSCs) enhance the growth of tumors by positively 
regulating the proliferation and/or self-renewal of ALDH+ 
CSCs. In addition, MSCs increased the mammosphere 
formation capacity of tumor cell lines in vitro (65) and the 
proportion of ALDH+ CSC-like cells in vivo (45). Similar 
results were obtained by McLean et al, who demonstrated 
that MSC-like cells isolated from human tumors induce 
the growth of tumors and the self-renewal of putative 
CSCs at least in part via BMP secretion  (which has been 
previously shown to be involved in tumor progression) 
(65). In addition, Quante et al suggested that the MSC-
derived myofibroblasts create a niche for stem-cell like 
MSCs. Molecules involved in the niche were likely 
BMP4, Wnt5a, IL-6, Gremlin-1, DKK, and Shh. This 
raises the question of whether similar molecules may 
be involved in the maintenance of the CSC niche (24). 
Intriguingly, a recent paper from the Weinberg laboratory 
found that a delicate crosstalk between MSCs and cancer 
cells plays roles in both inducing CSCs and regulating the 
phenotype of tumor-associated MSCs (64). Specifically, 
they found that secretion of IL-1 by tumor cells induces 
PGE2 secretion by MSCs; PGE2, in combination with 
upregulation of cytokines by MSCs, leads to activation 
of  β-catenin  signaling  in  cancer  cells  and  subsequent 
formation of CSCs. This paper not only emphasizes the 
plastic nature of CSCs, but also the dynamic interactions 
between CSCs and MSCs in cancer progression and 
maintenance.
Surprisingly,  Khakoo  et  al  found  that  Kaposi 
sarcoma tumors in mice are growth inhibited when 
in the presence of MSCs (34). It thus appears that 
MSC functional contribution to tumor progression is 
highly context dependent, with this inherent variation 
compounded by inconsistencies in MSC preparation. 
Indeed, differences may arise from differences in tumor 
models, MSC preparations, and timing and concentration 
of MSC administration (66). Carefully defining the roles 
of MSCs in regulating the initiation versus progression 
of tumors in the context of any experimental design 
will be essential for understanding the results of any 
experiments.  For example, some tumor cell lines growth 
in vivo is promoted by MSCs while others are not (within 
a single study). Also, another group observed that while 
high numbers of MSCs within tumors may promote 
tumor initiation, a low number of MSCs may have no 
or inhibitory effects, suggesting complex dosage effects 
in pro- and anti- initiation pathways which remain to be 
elucidated (67). In addition, Khakoo et al suggested a way 
in which tumor genetic context can influence the effect of 
MSCs on tumor progression. Inhibition of human Kaposi 
sarcoma cell growth was dependent on cell contact via 
E-cadherin and Akt inhibition (34). Thus, it would be of 
interest to conduct systematic loss and gain-of-function 
studies on endogenous MSCs and MSCs derived ex vivo, 
with different exogenous or endogenous tumor types 
(66). It is likely that tumor type, stage, and the genetic 
dependencies of the tumor all influence the exact roles of 
MSCs in regulating tumor progression or initiation.
Several studies suggest that MSCs promote tumor 
metastasis though secretion of SDF-1, CCL-5, and other 
chemokines. Tumor cells induced expression of CCL5   
(regulated and normal T cell expressed and secreted; 
RANTES) in MSCs, which in turn increased tumor 
migration and metastasis in a paracrine and/or endocrine 
manner (56). In support of this hypothesis, one group 
found that neuroblastoma tumor cells can migrate towards 
MSCs in vitro and that this response was dependent 
on SDF1-CXCR4 signaling (68). Moreover, MSC-
like cells have been proposed to contribute to the bone 
marrow hematopoietic niche and hence may promote the 
establishment of niches for metastatic cells (59). Thus, 
MSCs present in target tissues may induce migration of 
metastasizing tumor cells (5,59).
6. MSC USE IN CANCER THERAPY
In recent years, there has been considerable interest 
in the use of MSCs as trophic vehicles for delivery of 
drugs, proteins, and other therapeutic agents specifically 
to tumors. The advantage of using MSCs for drug delivery 
versus using other tumor-tropic cells such as macrophages 
include the immunoprivileged status of MSCs, homing 
abilities and intratumoral distribution, availability, 
genotypic and phenotypic stability, expandability, and 
proven safety record in clinical trials (69,70). Given the 
possibility of MSC regulation of tumor function it would 
be desirable to have viable drug-containing MSCs with 
stable functional properties until integration, distribution 
and drug release within tumors; however, once this has 
occurred, MSCs should die in order to avoid effects that 
facilitate tumor progression. The safe use of MSCs to 
treat cancer or non-cancer diseases in patients that have 
undiagnosed, early-stage cancer requires understanding the 
fate and functions of MSCs in vivo and their interactions 
with tumors. Figure 5 and Supplementary Table 4 
summarize the approaches in this field. To circumvent use 
of genetic engineering, incorporation of drug-laden nano/Oncotarget 2013; 4: 651-664 659 www.impactjournals.com/oncotarget
microparticles on the cell surface or intracellularly, has 
been done (Supplementary Table 4 and references therein).
7. CONCLUSIONS AND PERSPECTIVES
Endogenous and ex vivo cultured MSCs have been 
shown to specifically home to, integrate with, and survive 
in tumors. This property has successfully been used in 
experimental tumor therapies. Table 1 summarizes central 
questions remaining in the field and how they may be 
addressed with future work. Although we are beginning 
to understand how MSCs interact with tumors and how 
this can be exploited therapeutically, many questions and 
hurdles remain. 
Although both bone marrow, adipose, and local 
tissues are sources of tumor-associated MSCs, their 
relative contribution, kinetics, and regulation remain 
poorly understood. A solution is to label progeny of 
Table 1: Key Directions for Future Studies
Questions or problems Suggested solutions and approaches
MSC-cancer interactions
What distal tissues do MSCs mobilize from to contribute 
to tumors?
MSC labeling in different tissues (e.g., genetic via Cre 
recombinase) and tracking MSCs in tumors
What are the mechanisms of MSC mobilization to and 
survival in blood?
Identification of tumor-derived factors that mobilize MSCs 
from distal tissues
Two-photon intravital microscopy  (IVM) 
Function blocking
MSC survival and recovery assays in blood
MSC interaction with other blood cell types
In vivo and in vitro RNAi screening using labeled MSCs
What are the cell subtypes that MSCs differentiate to and 
what are the roles of these cells?
Detailed in vivo lineage characterization after MSC labeling   
(e.g., genetic via Cre recombinase); progeny isolation and 
characterization or in situ characterization
Depletion of MSC progeny via genetic, pharmacological, or 
other techniques; determine the effect on tumor progression
What are the mechanisms of MSC homing to, survival in, 
and organization  (differentiation and localization) within 
tumors and normal organs?
In vitro flow chamber
In vivo two-photon intravital microscopy  (IVM) and MSC-
surface aptamer sensors
Function blocking by antibodies, RNAi, or pharmacology
In vivo and in vitro screening using labeled MSCs
What are the mechanisms of MSC interaction with immune 
cells in cancers?
In vivo two-photon intravital microscopy (IVM) and MSC-
surface aptamer sensors
In vitro interaction studies of MSC with tumor and normal 
immune cells
What are the mechanisms of MSC interaction with cancer 
stem cells?
In vivo two-photon intravital microscopy (IVM) and MSC-
surface aptamer sensors
In vivo depletion of MSCs in tumors by genetic or 
pharmacological techniques, to determine effects on phenotype 
and proportion of cancer stem cells 
In vivo function blocking and proportion of cancer stem cells 
in tumors
MSC-based cancer therapeutics
Design of therapies targeting tumor microenvironment 
components
Use of knowledge of mechanisms of endogenous MSC 
homing, integration, and function in tumors to design therapies 
for blockade of tumor and metastatic progression
Localized drug delivery to tumors
Use of non-genetically engineered MSCs for in vivo drug 
delivery  (engulfed microparticles)
Integration of biology and therapy
Combinatorial modification of MSCs for enhanced homing   
(surface SLeX), single-cell tumor microenvironment imaging   
(surface aptamers), and multiple drug delivery (microparticles)
Combinatorial therapy using MSCs and other therapiesOncotarget 2013; 4: 651-664 660 www.impactjournals.com/oncotarget
local and distant MSCs to follow their fate and dynamic 
behavior in the tumor. However, the absence of specific 
and reliable markers of MSCs has been a hurdle to the 
generation of reporter mice. Current studies have therefore 
been limited to the use of BMT from labeled mice. The 
development of MSC reporter mice would provide an 
elegant and revolutionary tool for investigation of MSCs 
in cancer.
To better understand the recruitment of MSCs to 
tumors, it will be important to study the mechanisms 
of MSC mobilization and survival in the circulation 
in response to systemic cancer stimuli. Unclear are 
the molecular cues that promote emigration from their 
endogenous niche and the mechanisms of how they 
migrate through the source tissue. High resolution two-
photon intravital microscopy (IVM) will be instrumental in 
these efforts. Also, survival of MSCs may be mediated by 
cell-autonomous and non-cell autonomous mechanisms, 
including contact with leukocytes or platelets (71). MSCs 
express several integrins and their ligands, instrumental 
in binding to selectins, and have been reported to directly 
interact with leukocytes (72) and platelets (73). However, 
a major limitation in understanding the recruitment 
of MSCs has been isolation of viable cells from the 
circulatory system. Thus, it will be critical to develop 
methods for capture and analysis of MSCs from blood. 
Immunoseparation, size separation, and microfluidics may 
be applied to the reliable isolation of circulating MSCs 
(74). 
MSCs can contribute to several elements of the 
tumor stroma. The advent of deep-tissue imaging will 
undoubtedly shed valuable light on how MSCs contribute 
to the cellular organization of tumors (75). In combination 
with in vitro and in vivo functional assays, these studies 
may elucidate contributions of MSCs to tumors and their 
molecular mechanisms. In addition, we expect that single-
cell  based  approaches  will  contribute  significantly  to 
the understanding of MSC-tumor organization. To fully 
understand the roles of MSCs in cancer, it will be critical 
to perform detailed lineage tracing studies of cells derived 
from exogenous or endogenous MSCs and the effect on 
the tumor when these progeny are selectively depleted. 
Because MSC function in tumors is context dependent, it 
will be critical to evaluate the cause of this dependency by 
performing RNAi, overexpression, or drug screening for 
tumor and MSC factors that cause MSCs to promote or 
inhibit tumor growth in different tumor types.
Furthermore, the mechanisms of MSC homing 
to (rolling, adhesion, transmigration), survival in, and 
organization (differentiation and localization) within 
tumors and normal organs remain to be investigated 
systematically.  Specifically,  the  question  of  to  what 
extent selective interactions of MSCs with tumor blood 
vessels versus other blood vessels contributes to homing 
remains open, and may be answered with advent of IVM 
(75). In addition, questions remain as to the ability of 
MSCs to home to pre-metastatic (58), micrometastatic 
and macrometastatic growing and dormant  (e.g., in the 
bone) niches (76). Indeed, many of these steps cannot 
be recapitulated with tail-vein injections of tumor cells 
and require more complex animal models. Moreover, the 
ability of MSCs to home to metastases other than in the 
lung and liver remains to be established. Understanding if 
and how MSCs cross the blood-brain barrier for treatment 
of brain metastases will be critical. Finally do MSCs home 
more efficiently to these metastases, are they preferentially 
retained there, and/or does the niche promote their 
proliferation or survival?  
Also, MSC spatiotemporally organize themselves 
in tumors, contributing to different microenvironments, 
and differentiating into various tumor stroma cells. The 
significance and the mechanisms of this organization are 
unclear. Previous approaches of understanding cell fate 
and environment have been limited by low spatial and/
or temporal resolution, required genetic modifications of 
cells, and/or could not detect multiple molecules. Today, 
high-resolution two-photon IVM (75), coupled with 
spatiotemporal FRET-based aptamer microenvironment 
sensors (SMS; (77); Figure 5) can be used. Such studies 
would allow probing the spatiotemporal localization 
of MSCs and measuring the status of critical signaling 
molecules or events. By coupling these approaches with 
gain and loss of function studies, it will be possible to 
directly study the interactions between MSCs and tumors 
in vivo.
In addition, MSCs have tremendous therapeutic 
potential due to their immunomodulation, tumor homing 
and integration capacity, and ability to carry tumoricidal 
agents. To exploit this for therapy, it is critical to further 
develop non-genetically engineered MSCs for localized 
drug delivery.  Moreover, MSC homing to tumors may 
be improved and fine-tuned using genetic, enzymatic, and 
chemical modification of the MSC surface. For example, 
preformed  SLeX  or  P/L-selectin  targeting  aptamer 
moieties can be anchored to the MSC surface. These have 
been  shown to improve homing to inflamed endothelium 
both in vitro and in vivo (78–81).
An unexplored potential is use of MSCs in 
combinatorial therapies, such as incorporating MSC-
based therapies with traditional drug therapies, delivery of 
multiple drugs with one MSC preparation, or modification 
of both MSC homing and drug loading (Figure 5). As the 
regulation of cancer cell pathways and signaling by MSCs 
become better understood, it may be possible to target 
cancers through a combination of directed therapies and 
MSCs. Due to the tight association between cancer stem 
cells and MSCs, targeting the CSC population or niche 
with MSCs is also an interesting, unexplored direction.
Finally, therapies to modulate the mechanisms of 
endogenous MSC-tumor interaction have great potential. 
For example, therapies similar to those aimed at limiting 
leukocyte homing in inflammation, may also have utility Oncotarget 2013; 4: 651-664 661 www.impactjournals.com/oncotarget
in attenuating MSC homing to tumors. For instance, 
since TNF-α induced adhesion of MSCs to endothelial 
cells, anti-inflammatory drugs such as parthenolide could 
decrease MSC accumulation in tumors (82). Clinically, the 
utility of blocking MSC homing to tumors will clearly be 
context and diagnosis-dependent. In the end, these studies 
will shape our understanding of how tumors integrate with 
and exploit the biology of the whole organism.
We strongly believe that understanding how 
both endogenous and exogenous MSCs interact with 
cancer cells, both in the context of cancer biology 
and  therapeutics,  will  have  enormous  benefits  in  the 
future. Developing a solid mechanistic and biological 
understanding of MSCs in cancer will lead to not only 
improved MSC-based therapies, but open up new areas 
of research and unveil biology not previously appreciated.
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